Neoleukin Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in two investor conferences. The first is the BofA Securities 2022 Healthcare Conference in Las Vegas on May 11, 2022, featuring a fireside chat at 1:20 p.m. Pacific. The second event is the H.C. Wainwright Global Investment Conference in Miami on May 25, 2022, where Drachman will present at 12:30 p.m. Eastern. Webcasts for both presentations will be available on the Neoleukin investor website, with archived replays accessible for 30 days.

SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows:

BofA Securities 2022 Healthcare Conference – Las Vegas, NV

• Fireside chat
• Wednesday May 11, 2022, at 1:20 p.m. Pacific

H.C. Wainwright Global Investment Conference – Miami, FL

• Company presentation
• Wednesday, May 25, 2022, at 12:30 p.m. Eastern

The webcast presentations can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. Archived replays will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

What are the details of Neoleukin Therapeutics' participation in the BofA Securities 2022 Healthcare Conference?

Neoleukin CEO Jonathan Drachman will participate in the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 1:20 p.m. Pacific time.

When is Neoleukin Therapeutics' presentation at the H.C. Wainwright Global Investment Conference?

The presentation at the H.C. Wainwright Global Investment Conference is scheduled for May 25, 2022, at 12:30 p.m. Eastern time.

Where can I access the webcasts of Neoleukin Therapeutics' investor presentations?

Webcasts can be accessed from the investors section of the Neoleukin website, with archived replays available for at least 30 days after the events.

What is the focus area of Neoleukin Therapeutics?

Neoleukin Therapeutics focuses on creating next-generation immunotherapies for cancer, inflammation, and autoimmunity using advanced protein design technology.

What is the lead product candidate of Neoleukin Therapeutics?

Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist aimed at improving tolerability and efficacy.